J&J Antidepressant Relieves Symptoms, Enhances Sleep in Key Trial

Johnson & Johnson (J&J) announced encouraging results from a Phase 3 clinical trial of their new antidepressant, seltorexant. This medication, designed to complement existing treatments like SSRIs, has shown promising outcomes in alleviating depressive symptoms and improving sleep among participants with major depressive disorder and insomnia.

The study, conducted by J&J, focused on adults struggling with major depressive disorder who also suffer from insomnia—a common issue that traditional SSRIs often fail to address effectively. Although J&J has yet to release detailed data, the company confirmed that the study successfully met all primary and secondary goals. Notably, participants treated with seltorexant demonstrated significant and clinically meaningful improvements in depressive symptoms by day 43 of the study.

Johnson & Johnson has been a constant player in neuropsychiatry, even as other pharmaceutical giants like Bristol Myers Squibb and AbbVie exited and then reentered the field through substantial acquisitions. J&J has placed a considerable emphasis on their brain drug pipeline, with seltorexant being one of their most promising candidates. Company executives have previously forecasted that seltorexant could generate annual sales ranging from $1 billion to $5 billion.

Seltorexant targets the orexin-2 protein, a focus of interest for treating narcolepsy. Other companies like Takeda Pharmaceutical, Jazz Pharmaceuticals, and Alkermes are developing drugs that stimulate orexin-2 to help maintain wakefulness. However, in the context of depression, sleep disturbances such as insomnia are prevalent and can exacerbate the condition, increasing the risk of relapse. J&J has designed seltorexant as an orexin-2 antagonist, aiming to block the overstimulation of these receptors that leads to hyperarousal and sleep disturbances.

In addition to reducing depressive symptoms, seltorexant has also been shown to improve sleep quality. The trial included participants who had previously not responded well to SSRI or SNRI antidepressants and experienced significant sleep issues. The initial findings suggest that seltorexant could be a dual-purpose treatment, addressing both depression and the associated insomnia.

J&J plans to present a summary of the study findings at a medical conference in Miami, Florida, this week. The company also reported that seltorexant was safe and well-tolerated, with side effect rates comparable to those experienced by the placebo group.

Beyond seltorexant, J&J is also investing in another innovative depression medication called aticaprant. Results from a Phase 3 study of aticaprant are anticipated later this year, further underscoring J&J's commitment to advancing treatments for neuropsychiatric disorders.

In summary, seltorexant has shown promising results in treating both depressive symptoms and insomnia, offering hope for those who have not found relief with existing antidepressants. Johnson & Johnson's continued focus on innovative brain drugs highlights their dedication to addressing complex mental health issues and improving patient outcomes.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!